Navigation Links
'Good Clostridia' in the Gut Protect from Allergy and Autoimmunity
Date:12/23/2010

BOSTON, Dec. 23, 2010 /PRNewswire/ -- Scientists at the University of Tokyo have discovered that specific gut-dwelling bacteria control key immune cells that combat allergies and autoimmune diseases.  The paper describing these findings was published in today's issue of the journal Science, and technology originating from the work is being advanced by start-up Vedanta Biosciences.  

Dr. Kenya Honda and colleagues initially showed that mice raised in sterile conditions had deficient levels of regulatory T cells in their colon compared to mice colonized with microbes.  "Regulatory T cells are the peace-keepers of the immune system," says Dr. Alexander Rudensky, tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University, and Cornell University, whose previous work helped describe this specialized subset of T cells. "When these cells are missing, the body has trouble putting the brakes on excessive immune responses."

The team of researchers led by Honda then zeroed in on a subset of gut microbes belonging to the Clostridia class that were responsible for triggering production of regulatory T cells. Feeding these "Good Clostridia" to mice prevented the development of allergies and inflammatory bowel disease.  "For millions of years, we have co-evolved with our gut microbes, communicating in an ancient language that may hold critical clues about how autoimmune and infectious diseases develop," said Dr. Ruslan Medzhitov, Professor of Immunobiology at Yale, who authored pioneering studies of the innate immune system. "Researchers like Dr. Honda are making important strides to begin decoding this complex language."

This newly understood beneficial role of certain species of Clostridia may be reminiscent of the opposite effects on health of "good" and "bad" cholesterol.  While some species are harmful pathogens, such as C. difficile, many other Clostridia species are harmless or even beneficial as illustrated by Honda's work. "These surprising findings suggest we should revisit how we view this class of microbes," said Dr. Dan Littman, Professor of Molecular Immunology at NYU, whose previous work shed light on the development of Th17 cells in response to microbial signals. Dr. Littman added that Honda's findings "open up new treatment options for preventing and treating a number of immune-related disorders."

Honda's paper is the latest of a series of recent high profile publications that have followed the launch of the Human Microbiome Project by the NIH, and of similar international efforts aimed at exploring the roles of the human microbiome in health and disease. "The human microbiome is an exciting area of research that may enable a completely new class of therapies," said Dr. Ben Shapiro, Chairman and Senior Partner of PureTech Ventures and former EVP Worldwide Basic & External Research at Merck. "PureTech has made a significant commitment to translating research related to the microbiome, and we have a number of exciting technologies and programs under development."

About Vedanta Biosciences

Vedanta Biosciences, a privately held company, was co-founded by PureTech Ventures and a group of world renowned experts in immunology and microbiology. Vedanta Biosciences' mission is to develop a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. The technology developed by Dr. Honda and colleagues at the University of Tokyo forms the basis of one of several programs being advanced by the company. Dr. Medzhitov is the founding Chairman of the Scientific Advisory Board of Vedanta, and Dr. Rudensky, Dr. Littman, and Dr. Brett Finlay, Professor at the University of British Columbia and author of pioneering studies on molecular mechanisms of host-pathogen interaction, are founding members of the Scientific Advisory Board of Vedanta.  

About PureTech Ventures

PureTech Ventures is a Boston-based venture creation firm specializing in translating breakthrough research from top tier academic institutions into therapies that will significantly impact human health and well-being. PureTech's Partners include entrepreneurs and leaders from the top echelon of pharma, biotech and academia.


'/>"/>
SOURCE Vedanta Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Slo-Niacin® Dietary Supplement Shown to Support Good Cholesterol (HDL)
2. Timothy T. Goodnow, Ph.D., Joins Sensors for Medicine and Science, Inc. Board of Directors
3. Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline
4. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
5. OXIS International Executives Interviewed on StockGoodies.com Radio
6. Say Goodbye to Unwanted Love Handles: CoolSculpting by ZELTIQ™ Receives FDA Clearance for Patented, Non-Invasive Cooling Treatment for Fat Reduction
7. BMP Sunstones Hao Wawa (Good Baby) Brand Ranked First Among Chinas Top Three Pediatric Medicine Brands
8. Beijing Goodwill and IBM Team to Improve Detection of Cardiovascular Diseases
9. Purdue Pharma L.P. Provides Free Security Mobiles and Educational Safety Videos to Good Neighbor Pharmacy Members
10. LightLabs C7-XR FD-OCT Intravascular Imaging System Featured on Good Morning America
11. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):